

Suzanne E Dahlberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/66921/publications.pdf>

Version: 2024-02-01

116
papers

11,254
citations

26567

56
h-index

29081

104
g-index

120
all docs

120
docs citations

120
times ranked

15329
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>MET</i> Exon 14 Mutations in Nonâ€“Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression. <i>Journal of Clinical Oncology</i> , 2016, 34, 721-730.	0.8	549
2	Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790Mâ€“Positive Lung Cancer and Acquired Resistance to Osimertinib. <i>JAMA Oncology</i> , 2018, 4, 1527.	3.4	522
3	Prospective Validation of Rapid Plasma Genotyping for the Detection of<i>EGFR</i>and<i>KRAS</i>Mutations in Advanced Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 1014.	3.4	516
4	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 647-650.	0.6	414
5	Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers. <i>Lung Cancer</i> , 2015, 88, 108-111.	0.9	369
6	Outcomes for Elderly, Advanced-Stage Nonâ€“Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. <i>Journal of Clinical Oncology</i> , 2008, 26, 60-65.	0.8	358
7	Postinduction Dexamethasone and Individualized Dosing of <i>Escherichia Coli</i> L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Studyâ€“Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. <i>Journal of Clinical Oncology</i> , 2013, 31, 1202-1210.	0.8	274
8	Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 1042-1049.	0.8	273
9	Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions. <i>Journal of Thoracic Oncology</i> , 2013, 8, 179-184.	0.5	269
10	Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. <i>Journal of Thoracic Oncology</i> , 2016, 11, 556-565.	0.5	268
11	Safety of Programmed Deathâ€“1 Pathway Inhibitors Among Patients With Nonâ€“Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. <i>Journal of Clinical Oncology</i> , 2018, 36, 1905-1912.	0.8	268
12	Long-term outcome of a pediatric-inspired regimen used for adults aged 18â€“50 years with newly diagnosed acute lymphoblastic leukemia. <i>Leukemia</i> , 2015, 29, 526-534.	3.3	265
13	Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 2788-2797.	0.8	227
14	Oncogenic mutations in cervical cancer. <i>Cancer</i> , 2013, 119, 3776-3783.	2.0	225
15	Clinical Course of Advanced Nonâ€“Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599. <i>Journal of Clinical Oncology</i> , 2010, 28, 949-954.	0.8	220
16	Immune Checkpoint Inhibitor Outcomes for Patients With Nonâ€“Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. <i>Journal of Clinical Oncology</i> , 2019, 37, 1927-1934.	0.8	220
17	Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. <i>Cancer Discovery</i> , 2019, 9, 926-943.	7.7	220
18	The frequency and management of asparaginaseâ€“related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Danaâ€“Farber Cancer Institute consortium protocols. <i>British Journal of Haematology</i> , 2011, 152, 452-459.	1.2	216

#	ARTICLE	IF	CITATIONS
19	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1726-1735.	0.5	208
20	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. <i>Lancet Oncology</i> , The, 2013, 14, 619-626.	5.1	203
21	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 313.	3.4	171
22	A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 2972-2978.	1.3	166
23	The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 4169-4173.	0.6	162
24	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. <i>Nature Medicine</i> , 2012, 18, 1118-1122.	15.2	162
25	Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1416-1423.	0.5	153
26	Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501. <i>Journal of Clinical Oncology</i> , 2009, 27, 6006-6011.	0.8	148
27	A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500). <i>Journal of Thoracic Oncology</i> , 2007, 2, 1036-1041.	0.5	145
28	Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. <i>Pediatrics</i> , 2012, 130, 1003-1011.	1.0	142
29	Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. <i>Pediatric Blood and Cancer</i> , 2009, 53, 162-167.	0.8	137
30	Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1610-1623.	5.1	136
31	Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 222-229.	0.8	133
32	Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation for lower extremity peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2014, 59, 409-418.e3.	0.6	128
33	Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. <i>Blood</i> , 2007, 110, 1607-1611.	0.6	126
34	Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63.	0.5	119
35	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1661-1671.	5.1	115
36	Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 2845-2851.	0.6	112

#	ARTICLE	IF	CITATIONS
37	Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexamethasone. <i>Journal of Clinical Oncology</i> , 2008, 26, 1106-1111.	0.8	111
38	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2011, 208, 1595-1603.	4.2	104
39	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	3.2	104
40	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. <i>Clinical Cancer Research</i> , 2016, 22, 6010-6020.	3.2	100
41	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2851-2860.	3.2	96
42	Absence of Biallelic TCR β Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3816-3823.	0.8	93
43	Population-Based Outcomes Following Endovascular and Open Repair of Ruptured Abdominal Aortic Aneurysms. <i>Journal of Endovascular Therapy</i> , 2009, 16, 554-564.	0.8	92
44	Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation. <i>Cancer Discovery</i> , 2012, 2, 47-55.	7.7	89
45	Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 1818-1828.	0.6	88
46	Body Mass Index and Its Association with Clinical Outcomes for Advanced Non-Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1121-1127.	0.5	87
47	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	0.5	85
48	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019, 133, 96-102.	0.9	85
49	Outcomes following infrapopliteal angioplasty for critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2013, 57, 1455-1464.	0.6	77
50	Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non-Small-Cell Lung Cancer: The ECOG 3598 Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 616-622.	0.8	75
51	Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 881-94.	1.2	72
52	Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3148-3156.	3.2	71
53	Cytologic-Histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. <i>Cancer Cytopathology</i> , 2018, 126, 253-263.	1.4	70
54	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017, 23, 5737-5744.	3.2	69

#	ARTICLE	IF	CITATIONS
55	Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2013, 79, 283-288.	0.9	68
56	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. <i>Nature Medicine</i> , 2021, 27, 1910-1920.	15.2	62
57	Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599. <i>Journal of Thoracic Oncology</i> , 2011, 6, 103-108.	0.5	57
58	Prognostic Models to Predict Survival in Non-Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1361-1368.	0.5	57
59	Improving Clinical Trial Efficiency: Thinking outside the Box. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e141-e147.	1.8	57
60	Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). <i>Cancer</i> , 2016, 122, 2371-2378.	2.0	57
61	Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. <i>European Journal of Radiology</i> , 2015, 84, 998-1004.	1.2	54
62	A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). <i>Lung Cancer</i> , 2015, 89, 66-70.	0.9	52
63	Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. <i>Journal of Clinical Oncology</i> , 2019, 37, 2360-2367.	0.8	52
64	Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Patients Treated with EGFR TKI. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1059-1068.	0.5	48
65	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia. <i>Blood</i> , 2007, 110, 587-587.	0.6	47
66	Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	45
67	SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. <i>Oncogene</i> , 2012, 31, 4107-4116.	2.6	44
68	Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. <i>Cancer</i> , 2015, 121, 2570-2577.	2.0	42
69	Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2013, 119, 3761-3768.	2.0	40
70	Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1099-1106.	0.5	39
71	Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: Report from Dana-Farber Cancer Institute ALL Consortium Protocol 0001. <i>Pediatric Blood and Cancer</i> , 2011, 57, 492-498.	0.8	38
72	Fate of the contralateral limb after lower extremity amputation. <i>Journal of Vascular Surgery</i> , 2013, 58, 1571-1577.e1.	0.6	38

#	ARTICLE	IF	CITATIONS
73	Lower extremity arterial revascularization in obese patients. <i>Journal of Vascular Surgery</i> , 2007, 46, 738-742.	0.6	35
74	Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. <i>Academic Radiology</i> , 2016, 23, 329-336.	1.3	33
75	Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone: An Eastern Cooperative Oncology Group Study. <i>Journal of Thoracic Oncology</i> , 2010, 5, 885-892.	0.5	31
76	Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. <i>Lung Cancer</i> , 2012, 76, 410-415.	0.9	30
77	Baseline tumour measurements predict survival in advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2013, 109, 1476-1481.	2.9	30
78	Predictors of failure after angioplasty of infrainguinal vein bypass grafts. <i>Journal of Vascular Surgery</i> , 2009, 49, 117-121.	0.6	28
79	Use of <i>Ex Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2393-2403.	3.2	27
80	Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. <i>European Journal of Radiology Open</i> , 2019, 6, 128-131.	0.7	23
81	The <i>NQO1</i> *2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. <i>Oncology Reports</i> , 2011, 25, 1765-72.	1.2	21
82	Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 177-183.	1.1	21
83	Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). <i>Cancer</i> , 2015, 121, 2253-2261.	2.0	21
84	Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small-Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1295-1307.	0.5	16
85	Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. <i>Lung Cancer</i> , 2013, 81, 47-52.	0.9	15
86	Activity of erlotinib when dosed below the maximum tolerated dose for <i>EGFR</i> mutant lung cancer: Implications for targeted therapy development. <i>Cancer</i> , 2016, 122, 3456-3463.	2.0	15
87	Identification of a RAS-activating <i>TMEM87A</i> RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4072-4079.	3.2	13
88	Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1625-1637.	0.5	10
89	Clinical Versus Statistical Significance in Studies of Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1406-1408.	0.5	10
90	Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: <i>EGFR</i> -mutant non-small-cell lung cancer as a paradigm. <i>European Journal of Radiology</i> , 2018, 109, 68-76.	1.2	8

#	ARTICLE	IF	CITATIONS
91	Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. <i>Journal of Thoracic Imaging</i> , 2020, 35, 101-107.	0.8	7
92	P1-052: Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker. <i>Journal of Thoracic Oncology</i> , 2007, 2, S570.	0.5	5
93	M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. <i>Oncologist</i> , 2019, 24, e749-e754.	1.9	5
94	Use of an Educational Video to Improve Transgender Health Care Knowledge. <i>Clinical Pediatrics</i> , 2022, 61, 412-417.	0.4	5
95	Gefitinib for Recurrent Non-Small-Cell Lung Cancer: All Things Are Not Created Equal. <i>Journal of Clinical Oncology</i> , 2008, 26, 4233-4235.	0.8	4
96	Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. <i>European Journal of Radiology Open</i> , 2020, 7, 100210.	0.7	4
97	Peer-to-Peer Social Media Communication About Dietary Supplements Used for Weight Loss and Sports Performance Among Military Personnel: Pilot Content Analysis of 11 Years of Posts on Reddit. <i>JMIR Formative Research</i> , 2021, 5, e28957.	0.7	4
98	Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 960-967.	0.5	4
99	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia. <i>Blood</i> , 2006, 108, 1858-1858.	0.6	4
100	Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125.	1.3	4
101	E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 171-180.	1.1	3
102	A Proportional Hazards Cure Model for the Analysis of Time to Event with Frequently Unidentifiable Causes. <i>Biometrics</i> , 2007, 63, 1237-1244.	0.8	2
103	Evaluation of End Points in Cancer Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2018, 13, 745-747.	0.5	2
104	Pragmatic approaches to address expansion cohort design. <i>Cancer</i> , 2018, 124, 3290-3292.	2.0	2
105	Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition. <i>Blood</i> , 2011, 118, 1405-1405.	0.6	2
106	PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. <i>Journal of Thoracic Oncology</i> , 2007, 2, S468.	0.5	1
107	Attitudes towards involving children in decision-making surrounding lung transplantation. <i>Pediatric Pulmonology</i> , 2021, 56, 1534-1542.	1.0	1
108	Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). <i>JTO Clinical and Research Reports</i> , 2021, 2, 100166.	0.6	1

#	ARTICLE	IF	CITATIONS
109	The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols.. Blood, 2009, 114, 3073-3073.	0.6	1
110	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Cell Biology, 2011, 194, i4-i4.	2.3	1
111	Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. Journal of Clinical Oncology, 2022, 40, 2285-2287.	0.8	1
112	Meaningful Subset Analyses Contribute to Optimal Patient Care. Journal of Clinical Oncology, 2008, 26, 2064-2065.	0.8	0
113	Interpretation of Results from Underâ€accruing Studies. Oncologist, 2018, 23, 755-756.	1.9	0
114	Reply to N. Hanna et al and L. Xie et al. Journal of Clinical Oncology, 2020, 38, 771-772.	0.8	0
115	A Pilot Trial of Rapamycin with Glucocorticoids In Children and Adults with Relapsed ALL. Blood, 2010, 116, 3244-3244.	0.6	0
116	Abstract 87: SULF2 methylation is a prognostic biomarker for lung cancer survival and increases sensitivity to camptothecin analogues via expression of ISG15. , 2011, , .		0